VCM
CODX

Vanguard Capital Management’s Co-Diagnostics CODX Stock Holding History

Vanguard Capital Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181K Buy
+58,275
New +$179K ﹤0.01% 3829

Other funds holding CODX

PAG
Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SAM
Smartleaf Asset Management Boston, Massachusetts $3.08B AUM 27.39% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM

Vanguard Capital Management's CODX Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in Co-Diagnostics (CODX) in Q2 2026: 58,275 shares worth $181K. The stake represents ﹤0.01% of the portfolio and ranks #3829 among its holdings.

16 funds tracked by Wall St. Rank hold CODX as of Q2 2026.

  • Vanguard Capital Management held 58,275 shares of Co-Diagnostics worth $181K as of Q2 2026.
  • Co-Diagnostics was a new Vanguard Capital Management position in Q2 2026.
  • Co-Diagnostics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3829 holding.
  • 16 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.